Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FGFR3 Y373C

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Related tests:

therascreen® FGFR RGQ RT-PCR Kit (2)

therascreen® FGFR RGQ RT-PCR Kit (2)

FGFR3 Y373C	Urothelial Cancer	FGFR3 Y373C	Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR3 Y373C	Urothelial Cancer	FGFR3 Y373C	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3 Y373C	Urothelial Cancer	FGFR3 Y373C	Urothelial Cancer	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3
FGFR3 Y373C	Urothelial Cancer	FGFR3 Y373C	Urothelial Cancer	FGFR3 inhibitor Resistant: C3 – Early Trials FGFR3 inhibitor Resistant : C3	FGFR3 inhibitor Resistant: C3 – Early Trials FGFR3 inhibitor Resistant : C3
FGFR3 Y373C	Multiple Myeloma	FGFR3 Y373C	Multiple Myeloma	futibatinib Sensitive: D – Preclinical futibatinib Sensitive : D	futibatinib Sensitive: D – Preclinical futibatinib Sensitive : D
FGFR3 Y373C	Multiple Myeloma	FGFR3 Y373C	Multiple Myeloma	bortezomib Resistant: D – Preclinical bortezomib Resistant : D	bortezomib Resistant: D – Preclinical bortezomib Resistant : D